According to a new report, published by KBV research, The Global Cat Vaccine Market size is expected to reach $2.5 billion by 2031, rising at a market growth of 9.2% CAGR during the forecast period.
The Mono Vaccines segment is capturing a CAGR of 9.8% during (2024 - 2031). Mono vaccines targeting a single disease are essential for addressing specific health needs and use in cats with particular sensitivities or health conditions. These vaccines allow for tailored vaccination schedules and are often used for diseases such as rabies and feline leukemia. The ability to customize vaccination plans based on individual cat health and risk factors contributes to the significant revenue share of mono vaccines. Veterinarians and pet owners appreciate mono vaccines' flexibility in managing feline health.
The Injectables segment is generating the highest revenue in the Global Cat Vaccine Market by Route of Administration in 2023; thereby, achieving a market value of $1.8 billion by 2031. This is primarily due to injectable vaccines' widespread use and proven efficacy. Veterinarians commonly administer them during routine check-ups and are trusted for their reliable and long-lasting immunity. Injectable vaccines are versatile and cover a broad spectrum of diseases, including feline leukemia, panleukopenia, and rabies.
The 3 Year segment would exhibit a CAGR of 9.5% during (2024 - 2031). These vaccines are often used for diseases such as rabies and feline leukemia, providing long-term immunity with less frequent administration. The extended duration of immunity offered by these vaccines is particularly appealing to pet owners, as it reduces the number of veterinary visits required for booster shots, thereby offering greater convenience and cost-effectiveness.
The Feline Respiratory Diseases segment is leading the Global Cat Vaccine Market by Disease Type in 2023; thereby, achieving a market value of $706.2 million by 2031. The high prevalence and contagious nature of diseases like feline viral rhinotracheitis, feline calicivirus, and herpesvirus drive this. These respiratory infections can lead to severe cat health issues, necessitating regular vaccinations to prevent outbreaks. The effectiveness of vaccines in controlling these common and easily transmissible diseases makes them a priority for pet owners and veterinarians, thus propelling the segment's growth.
The Inactivated (Killed) segment is experiencing a CAGR of 9.6% during (2024 - 2031). The inactivated (killed) vaccine segment has grown, primarily due to its safety and stability. These vaccines are particularly useful for immunocompromised cats or those prone to adverse reactions from live vaccines. They are commonly used for diseases like rabies, which pose significant public health risks. The reliability and minimal side effects of inactivated vaccines make them a critical part of comprehensive vaccination programs, especially in regions with strict regulatory requirements, thus propelling their market growth.
Full Report: https://www.kbvresearch.com/cat-vaccine-market/
The North America region dominated the Global Cat Vaccine Market by Region in 2023; thereby, achieving a market value of $888.4 million by 2031. The Europe region is poised to grow at a CAGR of 8.9% during (2024 - 2031). Additionally, The Asia Pacific region would witness a CAGR of 9.8% during (2024 - 2031).
By Component
By Route of Administration
By Duration of Immunity
By Disease Type
By Type
Unique Offerings 
